Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

Osimertinib Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines and Durvalumab Shakes up SCLC

November 29th 2024

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Tiragolumab Plus Atezolizumab Fails to Meet OS End Point in PD-L1–High NSCLC

November 26th 2024

The addition of tiragolumab to atezolizumab did not significantly improve OS vs atezolizumab alone in PD-L1–high non–small cell lung cancer.

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

November 20th 2024

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

November 20th 2024

Zorifertinib has received NMPA approval in the first line for EGFR-mutant advanced or metastatic non–small cell lung cancer displaying CNS metastases.

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

November 19th 2024

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.

FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations

November 18th 2024

The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib.

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 18th 2024

The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

November 15th 2024

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Perioperative Nivolumab Plus Chemotherapy Represents the Future of Personalized NSCLC Care

November 14th 2024

Mark Awad, MD, PhD, and Jonathan Spicer, MD, PhD, discuss the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC

November 12th 2024

AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.